Federal State Unitary Enterprise "Federal Center of Nuclear Medicine Projects Design and Development" of FMBA of Russia as a Benchmark of the Nuclear Medicine Evolution in Russia

• Published in: Razrabotka i registraciâ lekarstvennyh sredstv (Online) Vol. 11; no. 2; pp. 16 - 25
• Main Authors: S. V. Loseva, O. N. Ilyushchenko, A. V. Antonyuk, T. V. Kishkina, O. A. Nagurnyy, M. A. Zolotarev, M. V. Goryacheva, A. V. Zverev, Yu. V. Rangaev
• Format: Journal Article
• Language: Russian
• Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 01-05-2022
• ISSN: 2305-2066; 2658-5049

Federal State Unitary Enterprise "Federal center of nuclear medicine projects design and development" of FMBA of Russia is the leading Russian manufacturer of therapeutic radiopharmaceutical preparations (RPP) is celebrating its 55th anniversary this year. The Enterprise was at the origin of the development of nuclear medicine in Russia and remains the largest manufacturer of therapeutic RPPs in our country. The account of the company's evolution is the story of the advancement of nuclear medicine in Russia. In the present article, we offer an analysis of the production experience the company accumulated over the years of operation as well as the major achievements and hardships the Enterprise dealt with. We put a special emphasis on the reciprocity of the Enterprise's background and progress with general trends in the development of nuclear medicine in Russia.